Senzime AB (publ) (SEZI.ST)
SEK 5.64
(-1.05%)
SEK 5.64
(-1.05%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -134.14 Million SEK | -1.09% |
| 2022 | -132.7 Million SEK | -61.55% |
| 2021 | -82.14 Million SEK | -73.13% |
| 2020 | -47.44 Million SEK | -40.89% |
| 2019 | -33.67 Million SEK | -31.44% |
| 2018 | -25.62 Million SEK | -96.68% |
| 2017 | -13.02 Million SEK | -38.41% |
| 2016 | -9.41 Million SEK | -24.16% |
| 2015 | -7.58 Million SEK | -22.43% |
| 2014 | -6.19 Million SEK | -10.61% |
| 2013 | -5.59 Million SEK | -27.44% |
| 2012 | -4.39 Million SEK | -109.13% |
| 2011 | -2.1 Million SEK | 10.8% |
| 2010 | -2.35 Million SEK | -36.78% |
| 2009 | -1.72 Million SEK | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q1 | -27.92 Million SEK | 28.03% |
| 2024 Q2 | -33.41 Million SEK | -19.63% |
| 2023 Q4 | -38.8 Million SEK | -28.61% |
| 2023 FY | -134.14 Million SEK | -1.09% |
| 2023 Q1 | -30.8 Million SEK | -54.85% |
| 2023 Q2 | -34.36 Million SEK | -11.56% |
| 2023 Q3 | -30.17 Million SEK | 12.19% |
| 2022 Q3 | -51.91 Million SEK | -28.62% |
| 2022 Q4 | -19.89 Million SEK | 61.68% |
| 2022 FY | -132.7 Million SEK | -61.55% |
| 2022 Q2 | -40.36 Million SEK | -96.52% |
| 2022 Q1 | -20.53 Million SEK | 13.61% |
| 2021 Q3 | -19.18 Million SEK | 13.02% |
| 2021 Q1 | -17.12 Million SEK | -12.72% |
| 2021 FY | -82.14 Million SEK | -73.13% |
| 2021 Q2 | -22.06 Million SEK | -28.83% |
| 2021 Q4 | -23.77 Million SEK | -23.9% |
| 2020 Q3 | -11.4 Million SEK | 9.91% |
| 2020 Q1 | -8.71 Million SEK | 1.58% |
| 2020 FY | -47.44 Million SEK | -40.89% |
| 2020 Q4 | -15.19 Million SEK | -33.26% |
| 2020 Q2 | -12.65 Million SEK | -45.26% |
| 2019 Q3 | -7.54 Million SEK | 10.93% |
| 2019 FY | -33.67 Million SEK | -31.44% |
| 2019 Q2 | -8.46 Million SEK | 4.04% |
| 2019 Q1 | -8.82 Million SEK | 16.81% |
| 2019 Q4 | -8.85 Million SEK | -17.39% |
| 2018 Q4 | -10.6 Million SEK | -97.21% |
| 2018 FY | -25.62 Million SEK | -96.68% |
| 2018 Q2 | -5.54 Million SEK | -35.23% |
| 2018 Q1 | -4.09 Million SEK | -11.66% |
| 2018 Q3 | -5.37 Million SEK | 2.99% |
| 2017 FY | -13.02 Million SEK | -38.41% |
| 2017 Q4 | -3.67 Million SEK | -49.53% |
| 2017 Q3 | -2.45 Million SEK | 16.21% |
| 2017 Q2 | -2.93 Million SEK | 26.2% |
| 2017 Q1 | -3.97 Million SEK | -11.14% |
| 2016 Q4 | -3.57 Million SEK | -81.87% |
| 2016 FY | -9.41 Million SEK | -24.16% |
| 2016 Q3 | -1.96 Million SEK | 2.96% |
| 2016 Q2 | -2.02 Million SEK | -9.29% |
| 2016 Q1 | -1.85 Million SEK | -2.24% |
| 2015 Q3 | -1.96 Million SEK | 9.21% |
| 2015 Q4 | -1.81 Million SEK | 7.95% |
| 2015 Q1 | -1.63 Million SEK | 0.15% |
| 2015 FY | -7.58 Million SEK | -22.43% |
| 2015 Q2 | -2.16 Million SEK | -32.67% |
| 2014 Q1 | -1.31 Million SEK | -20.26% |
| 2014 FY | -6.19 Million SEK | -10.61% |
| 2014 Q2 | -1.88 Million SEK | -43.39% |
| 2014 Q3 | -1.36 Million SEK | 27.44% |
| 2014 Q4 | -1.63 Million SEK | -19.94% |
| 2013 FY | -5.59 Million SEK | -27.44% |
| 2013 Q3 | -1.07 Million SEK | 37.82% |
| 2013 Q1 | -1.73 Million SEK | -67.84% |
| 2013 Q4 | -1.09 Million SEK | -1.28% |
| 2013 Q2 | -1.73 Million SEK | 0.0% |
| 2012 FY | -4.39 Million SEK | -109.13% |
| 2012 Q4 | -1.03 Million SEK | 0.0% |
| 2011 FY | -2.1 Million SEK | 10.8% |
| 2010 FY | -2.35 Million SEK | -36.78% |
| 2009 FY | -1.72 Million SEK | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Acarix AB (publ) | -77.83 Million SEK | -72.342% |
| ADDvise Group AB (publ) | 103.5 Million SEK | 229.613% |
| ADDvise Group AB (publ) | 103.5 Million SEK | 229.613% |
| Arcoma AB | 2.56 Million SEK | 5332.02% |
| Bactiguard Holding AB (publ) | -138.38 Million SEK | 3.059% |
| BICO Group AB (publ) | -835.7 Million SEK | 83.948% |
| Boule Diagnostics AB (publ) | 24.97 Million SEK | 637.09% |
| CellaVision AB (publ) | 130.3 Million SEK | 202.947% |
| Clinical Laserthermia Systems AB (publ) | -79.79 Million SEK | -68.123% |
| Chordate Medical Holding AB (publ) | -29.18 Million SEK | -359.624% |
| C-Rad AB (publ) | 35.52 Million SEK | 477.576% |
| Duearity AB (publ) | -26.19 Million SEK | -412.215% |
| Dignitana AB (publ) | -17.36 Million SEK | -672.614% |
| Episurf Medical AB (publ) | -94.8 Million SEK | -41.507% |
| Getinge AB (publ) | 2.41 Billion SEK | 105.562% |
| Scandinavian Real Heart AB (Publ) | -67.97 Million SEK | -97.344% |
| Iconovo AB (publ) | -45.89 Million SEK | -192.303% |
| Integrum AB (publ) | 4.03 Million SEK | 3426.714% |
| Luxbright AB (publ) | -25.37 Million SEK | -428.663% |
| Mentice AB (publ) | -2.81 Million SEK | -4662.123% |
| OssDsign AB (publ) | -130.49 Million SEK | -2.802% |
| Paxman AB (publ) | 8.33 Million SEK | 1710.432% |
| Promimic AB (publ) | -9.22 Million SEK | -1354.663% |
| Qlife Holding AB (publ) | -159.95 Million SEK | 16.134% |
| SciBase Holding AB (publ) | -55.58 Million SEK | -141.34% |
| ScandiDos AB (publ) | -14.64 Million SEK | -815.88% |
| Sectra AB (publ) | 428.38 Million SEK | 131.315% |
| Sedana Medical AB (publ) | -59.61 Million SEK | -125.037% |
| SpectraCure AB (publ) | -20.44 Million SEK | -556.274% |
| Stille AB | 26.64 Million SEK | 603.449% |
| Vitrolife AB (publ) | -3.85 Billion SEK | 96.517% |
| Xvivo Perfusion AB (publ) | 91.82 Million SEK | 246.1% |